Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regional Comparisons

Set Alert for Regional Comparisons

Exclusive analyses of drug review trends, approval decisions and regulatory guidance across regions.

Gene Therapy HTA: How Do The European, Australian And Canadian Systems Shape Up?

A report comparing the health technology assessment methods used in nine European countries, Australia and Canada found that England has the most favorable reimbursement landscape for gene therapies – but outlined several areas for improvement across the board.

Europe International

Swiss New Drug Approval Times On A Par With EMA, But Longer Than US FDA

The median approval time for new drugs in Switzerland lengthened in 2022, mainly because of applications filed during the peak of the COVID-19 pandemic, says the country’s regulator.

Europe Switzerland

How Do Japan’s Clinical Trial eConsent Rules Compare With The EU And US?

A newly-translated guidance document from Japan’s drug and device regulator outlines the points that clinical trial sponsors should consider when using electronic methods to collect informed consent from participants.

BioPharmaceutical Clinical Trials

Rare Diseases: European Market Access ‘Better Organized’ Than US, Says Rhythm

Rhythm is working with country-level authorities and centers of excellence in Europe to gain reimbursement and access for its obesity treatment Imcivree.

Europe EU

Different, But Not Poles Apart: Running Decentralized Clinical Trials In EU & US

This second segment of a two-part article on a regional comparison of EU and US approaches to decentralized clinical trials highlights the differences between the two regions relating to the more practical aspects of setting up and running such studies.

Clinical Trials Guidance Documents

FDA’s Decentralized Trial Guidance: Investigator, Health Care Provider Demarcation Raises Questions

The investigator's ability to delegate trial-related activities to local HCPs could create operational and reimbursement challenges, as well as potentially boost patient recruitment, stakeholders said. The guidance does not address digital divide and how to deal with a massive influx of data.

Clinical Trials Guidance Documents

Principles-Based vs Prescriptive: How US & EU Compare In Their Approach To Decentralized Trials

In this regional comparison, regulatory experts at a US-based decentralized clinical trials (DCT) firm discuss their views on how the FDA’s draft DCT guideline compares with the pan-EU recommendation paper on this topic. This first segment of a two-part article dwells on the thinking behind why US and EU regulators tend to go down different paths. 

Clinical Trials Guidance Documents

EMA And FDA Compared – The Case Of Minoryx’s Leriglitazone

The EMA offers more flexibility than the US FDA when it comes to missed primary endpoints in certain circumstances, meaning a potentially quicker route to authorization in the EU.

Europe North America

‘Faster Global Drug Approval’ Possible Under EMA’s Extended Reliance Framework

Drugs for Alzheimer’s disease, amyotrophic lateral sclerosis and other high unmet medical needs are among the new products that will now be eligible for assessment under the OPEN framework, the European Medicines Agency’s initiative for collaboratively assessing marketing applications with non-EU regulators.

Europe International

Status Quo: US Approvals For Pepaxto, Copiktra Remain Intact Despite Negative Panel Reviews

More than seven months after the Oncologic Drugs Advisory Committee voted that Pepaxto and Copiktra had negative benefit-risk profiles in their labeled indications, the drugs' approvals remain intact. Oncopeptides is still considering whether to heed the FDA's request to withdraw the Pepaxto NDA, even though the drug is not currently marketed. Secura Bio says Copiktra remains on the market and available for prescribing.

Post Market Regulation & Studies Review Pathway

Oncopeptides’ Melflufen: Same Data, Different Conclusions From EMA, US FDA

The two regulators were an OCEAN apart on their interpretation of the overall survival and progression-fee survival data from the Phase III confirmatory trial. European regulators saw fit to recommend Pepaxti’s approval, even after the drug was voluntarily discontinued in the US market due to FDA concerns.

Approvals Regional Comparisons

Where Do The EU & The US Stand On Decentralized Clinical Trials?

Guidance on regulatory and data protection considerations for decentralized clinical trials varies widely between the EU and the US. Trial sponsors need to pay particular attention to issues such as missing data, informed consent and data collection, say lawyers from Sidley Austin.

Europe Clinical Trials

Biosimilar Lucentis Sponsors Had To Navigate Different FDA, EMA Requirements

European Medicines Agency insisted on a stricter statistical analysis than the US FDA for demonstrating equivalence on the primary endpoint for both Coherus/BioEq’s Cimerli and Samsung Bioepis’ Byooviz; there also were differences in the regulators' preferred primary analysis population and primary endpoint interval.

Drug Review Profile Biosimilars

Ponvory’s Regulatory Timeline At The US FDA And EMA

Janssen’s ponesimod for relapsing multiple sclerosis had a slightly faster review in the US.

Drug Review Profile Regional Comparisons

Fatigue Benefit With Janssen’s MS Drug Ponvory Not Clinically Relevant – US/EU Regulators

In approving ponesimod for relapsing multiple sclerosis, neither the FDA nor EMA included in labeling data from a novel patient-reported outcomes fatigue instrument; FDA said the PRO was not shown to be capable of measuring within-patient change, while EMA said the difference relative to Sanofi’s Aubagio fell short of the threshold for a clinically meaningful benefit.

Drug Review Profile Drug Review

EU, US Reviewers Differed On Ponvory’s Secondary Endpoints, But Hierarchy Didn’t Matter In The End

Janssen went against EMA’s advice on the choice of secondary endpoints for its multiple sclerosis drug Ponvory (ponesimod), but still enjoyed a relatively brisk review. The hierarchical order of endpoints did not seem to ruffle any feathers among US FDA reviewers.

Drug Review Profile Drug Review